KIMS Q2 FY27 Results: Revenue Surges 39.9% YoY to ₹1,344 Crore, EBITDA Up 34%
Krishna Institute of Medical Sciences Limited (KIMS) reported Q2 FY27 revenue of ₹1,344.4 crore, a 39.9% year-on-year increase. EBITDA rose 34.0% to ₹278.9 crore. PAT for the quarter was ₹75.7 crore. IP volume grew 27.0% and OP volume increased by 23.3%. ARPOB and ARPP also saw increases.
The substantial revenue and EBITDA growth, coupled with strong operational performance, are material positive developments for the company, likely to be viewed favorably by investors.
The company reported strong year-on-year growth in revenue and EBITDA, along with significant increases in operational metrics like IP and OP volumes, indicating positive business performance.
Krishna Institute of Medical Sciences Limited (KIMS) announced its unaudited financial results for the second quarter and half-year ended September 30, 2026. The company reported a significant year-on-year increase in revenue, reaching ₹1,344.4 crore in Q2 FY27, a 39.9% jump from ₹960.7 crore in Q2 FY26. For the half-year ended September 30, 2026, total revenue stood at ₹2,523.9 crore, up 37.7% from ₹1,832.3 crore in the same period last year.
EBITDA for the second quarter of FY27 grew by 34.0% year-on-year to ₹278.9 crore, compared to ₹208.2 crore in Q2 FY26. The EBITDA margin was 20.5% for Q2 FY27. For the half-year, EBITDA increased by 27.2% to ₹518.7 crore.
Profit Before Tax (PBT) for Q2 FY27 was ₹106.6 crore, a slight increase of 10.1% from ₹96.8 crore in Q2 FY26. Profit After Tax (PAT) for the quarter was ₹75.7 crore, up 5.1% from ₹72.0 crore in the prior year's corresponding quarter. Basic Earnings Per Share (EPS) for Q2 FY27 was ₹1.81.
Operationally, KIMS saw a 27.0% increase in In-Patient (IP) volume to 81,668 in Q2 FY27 and a 23.3% rise in Out-Patient (OP) volume to 7,31,010. Average Revenue Per Operating Bed (ARPOB) increased by 14.9% to ₹48,277, and Average Revenue Per Patient (ARPP) rose by 9.9% to ₹1,65,577.
The company also provided a detailed breakdown of its performance across various regions, highlighting the ramp-up of operations in Kerala and Maharashtra, and significant achievements in Karnataka and Andhra Pradesh units. The investor presentation also showcased the company's corporate structure and revenue mix, with Cash contributing 53% and Insurance 32% to the payor mix.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.